NO333017B1 - Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. - Google Patents
Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne.Info
- Publication number
- NO333017B1 NO333017B1 NO20043401A NO20043401A NO333017B1 NO 333017 B1 NO333017 B1 NO 333017B1 NO 20043401 A NO20043401 A NO 20043401A NO 20043401 A NO20043401 A NO 20043401A NO 333017 B1 NO333017 B1 NO 333017B1
- Authority
- NO
- Norway
- Prior art keywords
- igfbp
- cancer
- antisense oligonucleotide
- seq
- antisense
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title claims abstract description 53
- 238000012230 antisense oligonucleotides Methods 0.000 title claims abstract description 53
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract description 25
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 title description 46
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 title description 46
- 238000000034 method Methods 0.000 title description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 230000001105 regulatory effect Effects 0.000 claims abstract description 15
- 230000000295 complement effect Effects 0.000 claims abstract description 14
- 230000002124 endocrine Effects 0.000 claims abstract description 14
- 101001044940 Homo sapiens Insulin-like growth factor-binding protein 2 Proteins 0.000 claims abstract description 5
- 102000050770 human IGFBP2 Human genes 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 101000840566 Homo sapiens Insulin-like growth factor-binding protein 5 Proteins 0.000 claims abstract description 3
- 108090000961 Insulin-like growth factor binding protein 5 Proteins 0.000 claims description 47
- 102000004371 Insulin-like growth factor binding protein 5 Human genes 0.000 claims description 47
- 108091034117 Oligonucleotide Proteins 0.000 claims description 47
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 24
- 206010060862 Prostate cancer Diseases 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 13
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 abstract description 17
- 210000004027 cell Anatomy 0.000 description 28
- 239000003098 androgen Substances 0.000 description 19
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 13
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 11
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 11
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 9
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 9
- 238000003753 real-time PCR Methods 0.000 description 7
- 241000282412 Homo Species 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 102000013275 Somatomedins Human genes 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 210000000988 bone and bone Anatomy 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 210000002307 prostate Anatomy 0.000 description 6
- 230000001605 fetal effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 108091008611 Protein Kinase B Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 3
- 206010027452 Metastases to bone Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 208000023958 prostate neoplasm Diseases 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 102000003780 Clusterin Human genes 0.000 description 2
- 108090000197 Clusterin Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 239000012828 PI3K inhibitor Substances 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 2
- 230000002424 anti-apoptotic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000010225 mixed cell type cancer Diseases 0.000 description 2
- 208000029638 mixed neoplasm Diseases 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000001621 anti-mitogenic effect Effects 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004409 osteocyte Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000017497 prostate disease Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35004602P | 2002-01-17 | 2002-01-17 | |
| PCT/CA2003/000061 WO2003062421A1 (en) | 2002-01-17 | 2003-01-17 | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043401L NO20043401L (no) | 2004-10-13 |
| NO333017B1 true NO333017B1 (no) | 2013-02-18 |
Family
ID=27613360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043401A NO333017B1 (no) | 2002-01-17 | 2004-08-16 | Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. |
Country Status (15)
| Country | Link |
|---|---|
| US (11) | US20030158143A1 (ja) |
| EP (1) | EP1465995B1 (ja) |
| JP (1) | JP4491240B2 (ja) |
| KR (2) | KR101166214B1 (ja) |
| AT (1) | ATE402999T1 (ja) |
| AU (1) | AU2003237616B2 (ja) |
| CA (1) | CA2469685C (ja) |
| DE (1) | DE60322509D1 (ja) |
| DK (1) | DK1465995T3 (ja) |
| ES (1) | ES2307942T3 (ja) |
| HU (1) | HU229452B1 (ja) |
| IL (2) | IL162540A0 (ja) |
| NO (1) | NO333017B1 (ja) |
| NZ (1) | NZ533126A (ja) |
| WO (1) | WO2003062421A1 (ja) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US7569551B2 (en) | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| IL162540A0 (en) * | 2002-01-17 | 2005-11-20 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| US7285541B2 (en) * | 2002-08-21 | 2007-10-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| KR101212512B1 (ko) | 2002-08-21 | 2012-12-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| AU2003297259A1 (en) * | 2002-11-14 | 2004-06-03 | Wyeth | Methods and compositions for treating neurological disorders |
| CA2539727C (en) * | 2003-10-01 | 2016-11-01 | The University Of British Columbia | Bispecific oligonucleotide for the treatment of cns malignancies |
| US8710020B2 (en) * | 2004-04-02 | 2014-04-29 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| US7482158B2 (en) * | 2004-07-01 | 2009-01-27 | Mathison Brian H | Composite polynucleic acid therapeutics |
| PT1814595E (pt) * | 2004-11-23 | 2014-04-02 | Univ British Columbia | Tratamento de cancro com uma combinação de um agente que perturba a via de sinalização egf e um oligonucleótido que reduz os níveis de clusterina |
| US7315916B2 (en) * | 2004-12-16 | 2008-01-01 | Sandisk Corporation | Scratch pad block |
| DK1937815T3 (en) * | 2005-09-13 | 2015-08-03 | Nat Res Council Canada | Methods and compositions for the modulation of tumor cell activity |
| EP2087152B1 (en) * | 2006-10-27 | 2015-03-11 | Walfish, Paul | Endometrial biomarkers |
| US8802826B2 (en) | 2009-11-24 | 2014-08-12 | Alethia Biotherapeutics Inc. | Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume |
| US9427429B2 (en) | 2010-03-01 | 2016-08-30 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| KR20140034838A (ko) * | 2011-05-19 | 2014-03-20 | 테바 파마슈티컬 인더스트리즈 리미티드 | 비소세포 폐암을 치료하는 방법 |
| CN103957923B (zh) | 2011-09-12 | 2018-05-25 | 卡维昂公司 | 用于抑制包括癌干细胞在内的干细胞的增殖、发育或分化的hs.459642单基因簇产物的拮抗剂 |
| BR112014020756A2 (pt) | 2012-02-22 | 2017-07-04 | Alethia Biotherapeutics Inc | co-uso de um inibidor da clusterina com um inibidor do egfr para tratar o câncer |
| CA2844640A1 (en) * | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
| MX2018004637A (es) | 2015-10-14 | 2019-05-06 | Bio Path Holdings Inc | Ácidos nucleicos p-etoxi para formulacion liposomal. |
| FI3364993T3 (fi) | 2015-10-22 | 2023-01-13 | Menetelmiä angelmanin oireyhtymän hoitamiseksi | |
| US10496215B2 (en) * | 2016-04-29 | 2019-12-03 | Synaptics Incorporated | Sensing for touch and force |
| KR20190053905A (ko) | 2016-09-16 | 2019-05-20 | 바이오-패쓰 홀딩스 인크. | 리포솜 안티센스 올리고뉴클레오타이드와의 병용 요법 |
| CA3053781A1 (en) | 2017-02-15 | 2018-08-23 | Cavion, Inc. | Benzopyran and naphalene derivatives and their uses as calium channel inhibitors |
| JP7237009B2 (ja) | 2017-04-19 | 2023-03-10 | バイオ－パス ホールディングス， インコーポレイテッド | Ｓｔａｔ３阻害のためのｐ－エトキシ核酸 |
| SG11201909960UA (en) | 2017-04-26 | 2019-11-28 | Cavion Inc | Methods for improving memory and cognition and for treating memory and cognitive disorders |
| KR102068302B1 (ko) | 2018-07-25 | 2020-01-20 | 정준모 | 봉투 고정장치 |
| TW202027728A (zh) | 2018-10-03 | 2020-08-01 | 美商卡凡恩公司 | 以(r)-2-(4-異丙基苯基)-n-(1-(5-(2,2,2-三氟乙氧基)吡啶-2-基)乙基)乙醯胺治療自發性震顫 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE913035A1 (en) | 1990-08-28 | 1992-03-11 | Chiron Corp | Genetic material encoding new insulin-like growth factor¹binding protein (igfbp-5) |
| ATE208816T1 (de) | 1990-08-28 | 2001-11-15 | Chiron Corp | Neues insulinähnliches wachstumsfaktor bindendes protein igfbp-5 |
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) * | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6365345B1 (en) * | 1993-12-23 | 2002-04-02 | Biognostik Gesellscahft Für Biomokekulare Diagnostik mbH | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| CA2246229C (en) * | 1996-02-14 | 2011-08-23 | Isis Pharmaceuticals Inc. | Sugar-modified gapped oligonucleotides |
| US5910583A (en) * | 1996-11-04 | 1999-06-08 | Duke University | Antisense oligonucleotides against ERBB-2 |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6210892B1 (en) * | 1998-10-07 | 2001-04-03 | Isis Pharmaceuticals, Inc. | Alteration of cellular behavior by antisense modulation of mRNA processing |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| GEP20032997B (en) | 1998-11-19 | 2003-06-25 | Warner Lambert Co | N-[4-(3-Chloro-4-Fluoro-Phenylamino)-7-(3-Morpholin-4-Yl-Propoxy)-Quinazolin-6-Yl]-crylamide, as an Irreversible Inhibitor of Tyrosine Kinases |
| AU3116800A (en) | 1998-12-11 | 2000-06-26 | Research Foundation Of The State University Of New York, The | Compositions and methods for altering cell migration |
| JP4785252B2 (ja) | 1999-02-26 | 2011-10-05 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Ｔｒｐｍ−２アンチセンス療法 |
| US6900187B2 (en) | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| WO2000069454A1 (en) * | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
| JP2003502383A (ja) * | 1999-06-21 | 2003-01-21 | マードック チルドレンズ リサーチ インスティチュート | 医学的障害の予防及び／又は治療のための方法 |
| CA2373721C (en) | 1999-07-02 | 2013-10-15 | Genentech, Inc. | Compounds that bind her2 |
| DE60038680T2 (de) * | 1999-07-19 | 2009-05-07 | The University Of British Columbia, Vancouver | Antisense-therapie für hormonregulierte tumoren |
| US6310047B1 (en) * | 1999-08-24 | 2001-10-30 | Virginia Commonwealth University | High affinity DNA binding compounds as adjuvants in antisense technology |
| AU2730801A (en) | 1999-12-21 | 2001-07-03 | Yale University | Survivin promotion of angiogenesis |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| DK2796553T3 (da) | 2000-03-30 | 2019-09-30 | Whitehead Inst Biomedical Res | Rna-sekvensspecifikke formidlere af rna-interferens |
| ATE507234T1 (de) * | 2000-09-14 | 2011-05-15 | Univ British Columbia | Antisense insulin-ähnliches wachstumsfaktor bindendes protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs |
| ES2728168T3 (es) * | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Moléculas pequeñas de ARN que median en la interferencia de ARN |
| US20030124513A1 (en) * | 2001-05-29 | 2003-07-03 | Mcswiggen James | Enzymatic nucleic acid treatment of diseases or conditions related to levels of HIV |
| US6750019B2 (en) * | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
| DE10152005A1 (de) | 2001-10-22 | 2003-04-30 | Bayer Cropscience Ag | Pyrazolylsubstituierte Heterocyclen |
| US20050123896A1 (en) | 2001-10-25 | 2005-06-09 | Benz Christopher C. | Screening system for modulators of her2 mediated transcription and her2 modulators identified thereby |
| IL162540A0 (en) * | 2002-01-17 | 2005-11-20 | Univ British Columbia | Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same |
| US7019017B2 (en) * | 2002-05-14 | 2006-03-28 | Baylor College Of Medicine | Small molecule inhibitors of HER2 expression |
| US7285541B2 (en) | 2002-08-21 | 2007-10-23 | The University Of British Columbia | Treatment of melanoma by reduction in clusterin levels |
| KR101212512B1 (ko) * | 2002-08-21 | 2012-12-26 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브 |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| CA2539727C (en) * | 2003-10-01 | 2016-11-01 | The University Of British Columbia | Bispecific oligonucleotide for the treatment of cns malignancies |
| PE20121495A1 (es) * | 2009-07-30 | 2012-11-19 | Antisense Pharma Gmbh | Combinacion de un agente quimioterapeutico y un inhibidor del sistema tgf-beta |
-
2003
- 2003-01-17 IL IL16254003A patent/IL162540A0/xx unknown
- 2003-01-17 DE DE60322509T patent/DE60322509D1/de not_active Expired - Lifetime
- 2003-01-17 AU AU2003237616A patent/AU2003237616B2/en not_active Ceased
- 2003-01-17 HU HU0402543A patent/HU229452B1/hu not_active IP Right Cessation
- 2003-01-17 CA CA 2469685 patent/CA2469685C/en not_active Expired - Fee Related
- 2003-01-17 WO PCT/CA2003/000061 patent/WO2003062421A1/en active Application Filing
- 2003-01-17 ES ES03731644T patent/ES2307942T3/es not_active Expired - Lifetime
- 2003-01-17 AT AT03731644T patent/ATE402999T1/de active
- 2003-01-17 US US10/346,493 patent/US20030158143A1/en not_active Abandoned
- 2003-01-17 JP JP2003562288A patent/JP4491240B2/ja not_active Expired - Fee Related
- 2003-01-17 DK DK03731644T patent/DK1465995T3/da active
- 2003-01-17 KR KR1020117003991A patent/KR101166214B1/ko not_active IP Right Cessation
- 2003-01-17 KR KR1020047011085A patent/KR101265180B1/ko not_active IP Right Cessation
- 2003-01-17 NZ NZ533126A patent/NZ533126A/en not_active IP Right Cessation
- 2003-01-17 EP EP20030731644 patent/EP1465995B1/en not_active Expired - Lifetime
-
2004
- 2004-06-15 IL IL16254004A patent/IL162540A/en active IP Right Grant
- 2004-08-16 NO NO20043401A patent/NO333017B1/no not_active IP Right Cessation
-
2005
- 2005-11-23 US US11/287,334 patent/US7973017B2/en not_active Expired - Fee Related
-
2008
- 2008-04-25 US US12/109,747 patent/US7928082B2/en not_active Expired - Fee Related
-
2010
- 2010-04-01 US US12/752,581 patent/US9101646B2/en not_active Expired - Fee Related
- 2010-12-27 US US12/978,940 patent/US8389491B2/en not_active Expired - Fee Related
-
2011
- 2011-04-15 US US13/087,627 patent/US8470796B2/en not_active Expired - Fee Related
- 2011-04-15 US US13/087,618 patent/US8252765B2/en not_active Expired - Fee Related
-
2012
- 2012-05-11 US US13/469,402 patent/US8541390B2/en not_active Expired - Fee Related
- 2012-10-11 US US13/649,654 patent/US8580761B2/en not_active Expired - Fee Related
-
2013
- 2013-05-29 US US13/904,457 patent/US8835401B2/en not_active Expired - Fee Related
-
2015
- 2015-07-02 US US14/790,293 patent/US20160002630A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO333017B1 (no) | Bispesifikke antisense-oligonukleotider som inhiberer IGFBP-2 og IFGBP-5 og anvendelse av slike samt farmasoytisk sammensetning og fremgangsmate for a fremstille denne. | |
| AU2003237616A1 (en) | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same | |
| US7297684B1 (en) | Antisense therapy for hormone-regulated tumors | |
| JP4874503B2 (ja) | 前立腺及びその他の内分泌腺腫瘍治療のためのアンチセンス・インシュリン様成長因子結合蛋白質（ｉｇｆｂｐ）−２オリゴデオキシヌクレオチド | |
| AU2001290920A1 (en) | Antisense insulin-like growth factor binding protein (IGFBP)-2-oligodeoxynucleotides for prostate and other endocrine tumor therapy | |
| US7491816B2 (en) | Antisense therapy for hormone-regulated tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |